KR101039110B1 - A water composition comprising Broussonetia kazinoki Sieb. for immunopotentiating - Google Patents
A water composition comprising Broussonetia kazinoki Sieb. for immunopotentiating Download PDFInfo
- Publication number
- KR101039110B1 KR101039110B1 KR1020080088388A KR20080088388A KR101039110B1 KR 101039110 B1 KR101039110 B1 KR 101039110B1 KR 1020080088388 A KR1020080088388 A KR 1020080088388A KR 20080088388 A KR20080088388 A KR 20080088388A KR 101039110 B1 KR101039110 B1 KR 101039110B1
- Authority
- KR
- South Korea
- Prior art keywords
- present
- mulberry
- water extract
- immune function
- extract
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title abstract description 34
- 240000006248 Broussonetia kazinoki Species 0.000 title description 8
- 235000006716 Broussonetia kazinoki Nutrition 0.000 title description 3
- 230000002434 immunopotentiative effect Effects 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 71
- 230000036737 immune function Effects 0.000 claims abstract description 41
- 235000013402 health food Nutrition 0.000 claims abstract description 8
- 238000005728 strengthening Methods 0.000 claims description 2
- 240000000249 Morus alba Species 0.000 abstract description 43
- 235000008708 Morus alba Nutrition 0.000 abstract description 43
- 230000002708 enhancing effect Effects 0.000 abstract description 26
- 210000002540 macrophage Anatomy 0.000 abstract description 22
- 230000000694 effects Effects 0.000 abstract description 19
- 238000004519 manufacturing process Methods 0.000 abstract description 18
- 201000010099 disease Diseases 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 210000004988 splenocyte Anatomy 0.000 abstract description 12
- 239000003814 drug Substances 0.000 abstract description 11
- 241000699670 Mus sp. Species 0.000 abstract description 7
- 229940124597 therapeutic agent Drugs 0.000 abstract description 7
- 230000002829 reductive effect Effects 0.000 abstract description 4
- 230000012010 growth Effects 0.000 abstract description 3
- 230000005934 immune activation Effects 0.000 abstract description 3
- 241000705930 Broussonetia papyrifera Species 0.000 abstract 1
- 230000003416 augmentation Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 235000013361 beverage Nutrition 0.000 description 9
- 230000004663 cell proliferation Effects 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 235000015203 fruit juice Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000011835 investigation Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- -1 broussoneone O Natural products 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000013882 gravy Nutrition 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000015192 vegetable juice Nutrition 0.000 description 3
- XFBBCGNJNJKLKS-UHFFFAOYSA-N 2-[3,4-dihydroxy-5-(3-methylbut-2-enyl)phenyl]-3,5,7-trihydroxy-8-(3-methylbut-2-enyl)chromen-4-one Chemical compound OC1=C(O)C(CC=C(C)C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C(CC=C(C)C)=C3O2)O)=C1 XFBBCGNJNJKLKS-UHFFFAOYSA-N 0.000 description 2
- SOQFBCLXNNQJDD-UHFFFAOYSA-N 2-[3,4-dihydroxy-5-(3-methylbut-2-enyl)phenyl]-3,5-dihydroxy-8,9,9-trimethyl-8h-furo[2,3-h]chromen-4-one Chemical compound C=12C(C)(C)C(C)OC2=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(CC=C(C)C)=C1 SOQFBCLXNNQJDD-UHFFFAOYSA-N 0.000 description 2
- WYEJSRSJEMZHNA-UHFFFAOYSA-N 3,5-dihydroxy-2-(8-hydroxy-2,2-dimethylchromen-6-yl)-8,9,9-trimethyl-8h-furo[2,3-h]chromen-4-one Chemical compound O1C(C)(C)C=CC2=CC(C=3OC=4C(C(C=3O)=O)=C(O)C=C3OC(C(C3=4)(C)C)C)=CC(O)=C21 WYEJSRSJEMZHNA-UHFFFAOYSA-N 0.000 description 2
- ADFDRHICFIZUNK-UHFFFAOYSA-N 4-[3-[8-hydroxy-2,2-dimethyl-5-(3-methylbut-2-enyl)-3,4-dihydrochromen-6-yl]propyl]-6-(2-methylbut-3-en-2-yl)benzene-1,3-diol Chemical compound C1=C(O)C=2OC(C)(C)CCC=2C(CC=C(C)C)=C1CCCC1=CC(C(C)(C)C=C)=C(O)C=C1O ADFDRHICFIZUNK-UHFFFAOYSA-N 0.000 description 2
- WDJNJKJPBQVUPY-UHFFFAOYSA-N 4-[3-[8-hydroxy-2,2-dimethyl-5-(3-methylbut-2-enyl)chromen-6-yl]propyl]-6-(2-methylbut-3-en-2-yl)benzene-1,3-diol Chemical compound C1=C(O)C=2OC(C)(C)C=CC=2C(CC=C(C)C)=C1CCCC1=CC(C(C)(C)C=C)=C(O)C=C1O WDJNJKJPBQVUPY-UHFFFAOYSA-N 0.000 description 2
- YXMLGIGHGPSEKA-AWEZNQCLSA-N 7,4'-Dihydroxyflavan Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2CC1 YXMLGIGHGPSEKA-AWEZNQCLSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- NQBROFAEMRVICP-UHFFFAOYSA-N papyriflavonol A Chemical compound OC1=C(O)C(CC=C(C)C)=CC(C2=C(C(=O)C3=C(O)C(CC=C(C)C)=C(O)C=C3O2)O)=C1 NQBROFAEMRVICP-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- RLBPSCXQOMYGEN-IWGURSETSA-N (4s,13r)-13-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]tridecane-1,4,13-triol Chemical compound OCCC[C@@H](O)CCCCCCCC[C@@H](O)[C@H]1N[C@H](CO)[C@@H](O)[C@@H]1O RLBPSCXQOMYGEN-IWGURSETSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HLJOKJJUFIWVNY-TVFCKZIOSA-N 13-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1-hydroxytridecan-5-one Chemical compound OCCCCC(=O)CCCCCCCC[C@H]1N[C@H](CO)[C@H](O)[C@@H]1O HLJOKJJUFIWVNY-TVFCKZIOSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- PNQQDEFGJPUAGZ-UHFFFAOYSA-N 5-[3-(2,4-dihydroxyphenyl)propyl]-3,4-bis(3-methylbut-2-enyl)benzene-1,2-diol Chemical compound C1=C(O)C(O)=C(CC=C(C)C)C(CC=C(C)C)=C1CCCC1=CC=C(O)C=C1O PNQQDEFGJPUAGZ-UHFFFAOYSA-N 0.000 description 1
- QSCBHDIGHKHWKC-NRFANRHFSA-N 6-[(2s)-7-hydroxy-3,4-dihydro-2h-chromen-2-yl]-2,2-dimethyl-7-(3-methylbut-2-enyl)chromen-8-ol Chemical compound C1CC2=CC=C(O)C=C2O[C@@H]1C1=CC(C=CC(C)(C)O2)=C2C(O)=C1CC=C(C)C QSCBHDIGHKHWKC-NRFANRHFSA-N 0.000 description 1
- PXCDCCIOLQVCFE-UHFFFAOYSA-N 6-[7-hydroxy-6-(2-methylbut-3-en-2-yl)-3,4-dihydro-2h-chromen-2-yl]-2,2-dimethyl-5-(3-methylbut-2-enyl)-3,4-dihydrochromene-3,8-diol Chemical compound C1CC2=CC(C(C)(C)C=C)=C(O)C=C2OC1C1=CC(O)=C2OC(C)(C)C(O)CC2=C1CC=C(C)C PXCDCCIOLQVCFE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 240000007068 Agaricus silvaticus Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000933832 Broussonetia Species 0.000 description 1
- OUMAXXFKYZEZHE-UHFFFAOYSA-N Broussonetine R Natural products COC1NC(C(O)CCC2=C(CCCCO)CCCC2=O)C(O)C1O OUMAXXFKYZEZHE-UHFFFAOYSA-N 0.000 description 1
- TWDNTWGVPATUAQ-UHFFFAOYSA-N Broussonetine S Natural products COC1NC(C(O)CCCCCCCCC(O)CCCO)C(O)C1O TWDNTWGVPATUAQ-UHFFFAOYSA-N 0.000 description 1
- GIIZXIOPWPQLLJ-UHFFFAOYSA-N Broussonetine W Natural products OC1C(O)C(CO)NC1CCCCCCCC1=CCCCC1=O GIIZXIOPWPQLLJ-UHFFFAOYSA-N 0.000 description 1
- 101100008044 Caenorhabditis elegans cut-1 gene Proteins 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- YXMLGIGHGPSEKA-UHFFFAOYSA-N Demethylbroussin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2CC1 YXMLGIGHGPSEKA-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- QXHVECWDOBLWPW-UHFFFAOYSA-N Kazinol A Natural products OC1=C(O)C(CC=C(C)C)=CC(C2OC3=CC(O)=CC=C3CC2)=C1CC=C(C)C QXHVECWDOBLWPW-UHFFFAOYSA-N 0.000 description 1
- QXHVECWDOBLWPW-QFIPXVFZSA-N Kazinol A Chemical group OC1=C(O)C(CC=C(C)C)=CC([C@H]2OC3=CC(O)=CC=C3CC2)=C1CC=C(C)C QXHVECWDOBLWPW-QFIPXVFZSA-N 0.000 description 1
- RPBKTSQYNACKIG-MHZLTWQESA-N Kazinol E Chemical compound CC(C)=CCC1=C(O)C(O)=CC([C@H]2OC3=CC(O)=C(C=C3CC2)C(C)(C)C=C)=C1CC=C(C)C RPBKTSQYNACKIG-MHZLTWQESA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241000745768 Pluchea carolinensis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- SEFQVLVYMCUORS-UHFFFAOYSA-N broussonetine Natural products Oc1cccc2c(ccnc12)C3CC(=O)OC3c4ccnc5c(O)cccc45 SEFQVLVYMCUORS-UHFFFAOYSA-N 0.000 description 1
- QZTNFEXLVDIXEF-UHFFFAOYSA-N broussonetine C Natural products OCCCC(=O)CCCCCCCCCC1NC(CO)C(O)C1O QZTNFEXLVDIXEF-UHFFFAOYSA-N 0.000 description 1
- ZKIXVIVMKROOOR-UHFFFAOYSA-N broussonetine J2 Natural products OC1C(O)C(CO)NC1CCCCCCC(O)C(O)C1NCCCC1 ZKIXVIVMKROOOR-UHFFFAOYSA-N 0.000 description 1
- RESBTRYGXXYJTJ-UHFFFAOYSA-N broussonetine M1 Natural products OCCCCC(O)CCCCCCCCC1NC(CO)C(O)C1O RESBTRYGXXYJTJ-UHFFFAOYSA-N 0.000 description 1
- QBJZCPGUZSTYAG-UHFFFAOYSA-N broussonetine O Natural products OCCCC(=O)CCCCCC=CCCC1NC(CO)C(O)C1O QBJZCPGUZSTYAG-UHFFFAOYSA-N 0.000 description 1
- JQEXPIWMLFOZCF-UHFFFAOYSA-N broussonetine T Natural products COC1NC(C(O)CCCC(O)CCCCC(=O)CCCO)C(O)C1O JQEXPIWMLFOZCF-UHFFFAOYSA-N 0.000 description 1
- CMHLWFDIUYEHTJ-UHFFFAOYSA-N broussonetine U1 Natural products OCCCC(=O)CCCCCCCCCC1=NC(CO)C(O)C1O CMHLWFDIUYEHTJ-UHFFFAOYSA-N 0.000 description 1
- XZKKUHFZPYQKNG-UHFFFAOYSA-N broussonetine X Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)NC1CCCCCCCC1=CCCCC1=O XZKKUHFZPYQKNG-UHFFFAOYSA-N 0.000 description 1
- HLJOKJJUFIWVNY-UHFFFAOYSA-N broussonetinine B Natural products OCCCCC(=O)CCCCCCCCC1NC(CO)C(O)C1O HLJOKJJUFIWVNY-UHFFFAOYSA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229930188348 kazinol Natural products 0.000 description 1
- FKFRARXIAGYPHF-UHFFFAOYSA-N kazinol B Natural products CC1Oc2c(O)c(CC=C(C)C)c(cc2C=C1)C3(C)CCc4ccc(O)cc4O3 FKFRARXIAGYPHF-UHFFFAOYSA-N 0.000 description 1
- RPBKTSQYNACKIG-UHFFFAOYSA-N kazinol E Natural products CC(C)=CCC1=C(O)C(O)=CC(C2OC3=CC(O)=C(C=C3CC2)C(C)(C)C=C)=C1CC=C(C)C RPBKTSQYNACKIG-UHFFFAOYSA-N 0.000 description 1
- CQZSYWYQTMUXRN-UHFFFAOYSA-N kazinol F Natural products CC(=CCc1c(O)c(O)cc(CCc2ccc(O)cc2O)c1CC=C(C)C)C CQZSYWYQTMUXRN-UHFFFAOYSA-N 0.000 description 1
- QRZIJQZCIHKOHL-UHFFFAOYSA-N kazinol H Natural products C1CC2=CC(C(C)(C)C=C)=C(O)C=C2OC1C1=C(CC=C(C)C)C(C=CC(C)(C)O2)=C2C(O)=C1 QRZIJQZCIHKOHL-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 닥나무 물 추출물을 함유하는 면역기능 강화용 조성물에 관한 것으로, 구체적으로 본 발명의 닥나무 물 추출물은 생쥐의 비장세포 및 대식 세포의 생장을 촉진하고 NO 생성을 촉진하므로, 본 발명의 닥나무 물 추출물이 면역 활성화 및 증강 효과가 있음을 확인하였으며, 본 발명의 닥나무 물 추출물은 면역기능 강화용 조성물, 면역기능 강화용 건강식품 및 면역기능 저하로 인한 질환의 치료제로 유용하게 이용될 수 있다. The present invention relates to a composition for enhancing immune function containing the water extract of the mulberry, specifically, the mulberry water extract of the present invention promotes the growth of splenocytes and macrophages of mice and promotes the production of NO, the mulberry water of the present invention It was confirmed that the extract has an immune activation and augmentation effect, the water extract of the mulberry of the present invention can be usefully used as a composition for enhancing immune function, health food for enhancing immune function, and a therapeutic agent for diseases caused by reduced immune function.
닥나무, 면역기능 강화. Paper mulberry, enhance immune function.
Description
본 발명은 닥나무 물 추출물을 함유하는 면역기능 강화용 조성물, 닥나무 물 추출물을 함유하는 면역기능 강화용 건강식품 및 닥나무 물 추출물을 함유하는 면역기능 저하로 인한 질환용 치료제에 관한 것이다.The present invention relates to a composition for enhancing immune function containing the water extract of mulberry, a health food for enhancing the immune function containing the water extract of mulberry and a therapeutic agent for a disease due to a decrease in immune function containing the water extract of mulberry.
닥나무(Broussonetia kazinoki)는 한자어로는 저목(楮木)이라고 한다. 학명은 Broussonetia kazinoki SIEB., 뽕나무과(Moraceae)의 낙엽활엽관목으로 산언저리 양지쪽에서 볼 수 있는데, 작은 가지에 짧은 털이 밀생하지만 자라면서 없어지고 수피는 회갈색이며, 높이는 약 3 m 정도이다. 잎은 난형 혹은 장타원형으로 가장자리에 날카로운 톱니가 있으며, 벌레가 먹은 것처럼 제각각의 모양으로 찢어져 있다. 꽃은 적자색으로 5-6월에 자웅이주형태로 액출하며, 열매는 핵과로서 구형이며 9월경에 성숙한다. 닥나무는 한방에서 근피를 구피마(構皮麻), 과실을 저실자(楮實子)라 하여 어린가지 및 잎과 함께 여름과 가을철에 채취한다. 잎은 호생하고 난형 또는 난상 타원형이며 긴 점첨두이고 원저 또는 아심장저이며 길이 5-20 cm로서 끝은 날카롭고 간혹 깊이 갈라진 것도 있으며 가장자리에 날카로운 톱니가 있다. 어린 나무에는 2-3개의 결각이 지는 것도 있다. 표면은 거칠며 뒷면은 처음에 털이 있다. 엽병은 길이 1-2cm로서 꼬부라진 털이 있으나 점차 없어진다 (국가생물종지식정보시스템, http://www.nature.go.kr/plant/plantGuide/). 닥나무는 옛날에는 저포라고 불리는 일종의 피륙을 짜는 데 사용되었고, 제지원료로 사용된다. 닥나무를 제지원료로 가공하려면 먼저 수확된 줄기를 1∼2 m 길이로 잘라 밀폐된 솥에 넣고 증기로 찐다. 두 시간 정도 쪄주면 처음 흙냄새가 나다가 단 맛을 띤 향기를 풍기는데, 이 무렵에 꺼내어 껍질을 벗긴다. 이것을 그대로 말린 것을 흑피(黑皮) 또는 조피(粗皮)라고 부르며, 다시 가공하여 백피(白皮)를 얻을 수가 있다. 보통 제지원료로 사용되는 것은 백피이지만, 백피를 제조할 때 긁어낸 검은 껍질도 하급지 원료로 사용된다 (造林技術(金容寬, 英崙社, 1962), 特用林産物栽培와 利用(尹國炳, 英崙社, 1963), 특용수재배학(임경빈, 향문사, 1976), 농산물상품편람(농업협동조합중앙회, 1983), 韓國樹木圖鑑(林業試驗場, 1966), 닥나무재배와 이용(김영련, 산림, 산림조합연합회, 1973)). 약리 작용으로는 거습, 이뇨, 활혈, 류머티즘에 의한 비통, 수종, 타박상, 피부염에 효과가 있다고 알려져 있으며, 화학 성분으로는 Kazinol A, Kazinol B, Kazinol D, Kazinol E, Kazinol F, Kazinol K, Kazinol H, Kazinol Q, Kazinol R, broussonetine W, broussonetine X, broussonetine M1, broussonetine U1, broussonetine J3, broussonetine J2, broussonetine R, broussonetine S, broussonetine T, broussonetine V, broussonetine O, broussonetine P, broussonetine Q, broussonol A, broussonol B, broussonol C, broussonol D, and broussonol E, broussonetinine A, broussonetinine B, 7,4'-dihydroxyflavan, oleanolic acid 등이 함유하고 있다고 알려져 있다.Paper mulberry ( Broussonetia) kazinoki ) is called kanji in Chinese. Scientific name is Broussonetia kazinoki SIEB., a deciduous broad-leaved shrub of the Moraceae family, found on both sides of the mountain, with small hairs growing on the branches, but disappearing as they grow, the bark is grayish brown, about 3 m high. The leaves are ovate or oblong in shape, with sharp teeth on the edges, and are torn in the shape of the insect as eaten. Flowers are reddish purple and discharged in the form of male to female in May-June. Fruits are nucleus spherical and mature in September. The mulberry is collected from the oriental medicine in the summer and autumn together with young branches and leaves. Leaves are regenerated, egg-shaped or egg-shaped oval, long apex, round or subcardiac, 5-20 cm long, with sharp ends, sometimes deeply split, with sharp teeth on the edges. Young trees have 2 to 3 missing lobes. The surface is rough and the back is initially hairy. The petiole is 1-2cm long, with curly hairs but gradually disappears (National Species Information System, http://www.nature.go.kr/plant/plantGuide/). The old mulberry tree was once used to weave a kind of skin called a follicle and used as a support fee. To process the paper mulberry as a support material, first cut the harvested stems into 1 to 2 m lengths and steam them in a closed pot. After two hours of steaming, it smells like earth and gives off a sweet scent. Dried as it is called black skin or black skin (粗 皮), and can be processed again to get white skin (白皮). It is commonly used as a refining fee, but the black skin scraped from the manufacture of white skin is also used as a raw material for the lower grade (造林 技術 (金 容 寬, 英 崙, 1962), 特 用 林 産物 栽培 and 利用 (尹國炳, 英 崙). 1963), Specialty Water Cultivation (Lim Kyung-bin, Hyangmun-sa, 1976), Agricultural Products Handbook (National Association of Agricultural Cooperatives, 1983), 韓國 樹木 圖鑑 (林業 試驗場, 1966) Federation, 1973). Its pharmacological action is known to be effective against roughness, diuresis, blood loss, rheumatism, pain, edema, bruises and dermatitis.The chemical composition of Kazinol A, Kazinol B, Kazinol D, Kazinol E, Kazinol F, Kazinol K, Kazinol H, Kazinol Q, Kazinol R, broussonetine W, broussonetine X, broussonetine M1, broussonetine U1, broussonetine J3, broussonetine J2, broussonetine R, broussonetine S, broussonetine T, broussoneone O, broussonetine O, brousus It is known to contain broussonol B, broussonol C, broussonol D, and broussonol E, broussonetinine A, broussonetinine B, 7,4'-dihydroxyflavan, and oleanolic acid.
면역 활성화를 검증하는 대표적인 방법으로 대식세포 증식 효과 (Friedl R, Moeslinger T, Kopp B, and Spiecke- rmann PG. Stimulation of nitric oxide synthesis by the aqueous extract of Panax ginsena root in Raw 264.7 cells. British Journal of pharma- cology, 2001;134:1663-1670.)와 비장세포의 증식 효과를 선택하였다. NO의 생성 촉진 효과는 대식세포 활성화의 지표로 대식세포에서 생성되는 NO는 침입한 병원치를 없애고 기본적인 숙주 방어체계를 작동시키는 역할을 한다(Farrell AJ, Blake DR. Nitric oxide. Annals of the Rheumatic Dieases. 1996;55:7-20.). 특히 Th 세포의 분화단계 중 ThO 상태에서 Thl과 Th2로 나누어질 때, Thl로의 분화를 돕는 작용을 하는 것으로 알려져 있다. 또한 백혈구의 활성 중 암세포, 기생충 또는 박테리아를 살해하는 세포독성 활성은 NO를 유리시킴으로써 나타나는 것으로 보고되고 있다(Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB Journal. 1992;6: 3051-3064.). 또한 기관지 염증에 NO가 T-cell과 내피세포간의 immunomodulating을 하며 (Bingisser RM, Holt PG Immunomodulating mechanism in the lower respiratory tract; nitric oxide mediated intraction between alveolar macrophage, epithelial cell, and T-cell, SWISS Medical Weekly. 2001;131;171-179.) 강력한 혈소판 응집 억제작용이 있다는 것이 알려져 있다. Representative methods of verifying immune activation are macrophage proliferation effects (Friedl R, Moeslinger T, Kopp B, and Spiecke-rmann PG.Stimulation of nitric oxide synthesis by the aqueous extract of Panax ginsena root in Raw 264.7 cells.British Journal of pharma -cology, 2001; 134: 1663-1670.) and the proliferative effects of splenocytes were selected. NO is a marker of macrophage activation. NO produced in macrophages acts to eliminate invading pathogens and activate basic host defenses (Farrell AJ, Blake DR. Nitric oxide. Annals of the Rheumatic Dieases. 1996; 55: 7-20.). Particularly, when Thl and Th2 are divided in the ThO state during the differentiation of Th cells, it is known to have a function of helping to differentiate into Thl. In addition, cytotoxic activity of killing cancer cells, parasites or bacteria among leukocyte activity has been reported to be released by the release of NO (Nathan C. Nitric oxide as a secretory product of mammalian cells.FASEB Journal. 1992; 6: 3051-3064) .). In addition, NO induced immunomodulating between T-cell and endothelial cells (Bingisser RM, Holt PG Immunomodulating mechanism in the lower respiratory tract; nitric oxide mediated intraction between alveolar macrophage, epithelial cell, and T-cell, SWISS Medical Weekly. 2001; 131; 171-179.) It is known that there is a potent platelet aggregation inhibitory effect.
이에 본 발명자들은 닥나무 물 추출물이 비장 세포 및 대식 세포의 증식을 촉진하며, NO의 생성을 유발하므로 닥나무 물 추출물이 면역 활성화 및 증강 효과가 있음을 확인하므로써 본 발명을 완성하였다.Accordingly, the present inventors completed the present invention by confirming that the water extract of mulberry promotes the proliferation of splenocytes and macrophages, and induces the production of NO.
본 발명의 목적은 닥나무 물 추출물을 유효성분으로 함유하는 면역기능 강화용 조성물, 닥나무 물 추출물을 유효성분으로 함유하는 면역기능 강화용 건강식품 및 이를 유효성분으로 하는 면역기능 저하로 기인한 질환의 치료제를 제공하는 것이다.An object of the present invention is a composition for enhancing immune function containing the water extract of the mulberry as an active ingredient, health foods for enhancing the immune function containing the water extract of mulberry as an active ingredient and a therapeutic agent for diseases caused by a decrease in immune function using the same as an active ingredient To provide.
본 발명은 물로 추출된 닥나무 추출물을 유효성분으로 함유하는 면역기능 강화용 조성물을 제공한다.The present invention provides a composition for enhancing immune function, which contains the extract of the mulberry extract as water as an active ingredient.
또한, 본 발명은 상기 면역기능 강화용 조성물을 유효성분으로 함유하는 면역기능 강화용 건강식품을 제공한다.In addition, the present invention provides a health food for enhancing immune function containing the composition for enhancing immune function as an active ingredient.
또한, 본 발명은 상기 면역기능 강화용 조성물의 제조방법을 제공한다.In addition, the present invention provides a method for producing the composition for enhancing immune function.
또한, 본 발명은 상기 면역기능 강화용 조성물을 유효성분으로 함유하는 면역기능 저하로 기인하는 질환용 치료제를 제공한다.In addition, the present invention provides a therapeutic agent for diseases caused by a decrease in immune function containing the composition for enhancing immune function as an active ingredient.
아울러, 본 발명은 면역기능 저하로 인한 질환의 치료 방법을 제공한다.In addition, the present invention provides a method for the treatment of diseases caused by impaired immune function.
본 발명의 닥나무 물 추출물은 생쥐의 비장세포 및 대식 세포의 생장을 증가시키고, NO의 생성을 증가시키므로 면역기능의 강화에 효과적이므로, 면역기능 강 화용 조성물, 면역기능 강화용 건강식품 및 면역기능 저하로 기인하는 질환용 치료제로 이용하는데 유용하다.Since the water extract of the mulberry of the present invention increases the growth of splenocytes and macrophages in mice, and increases the production of NO, it is effective for strengthening immune function, and thus, composition for enhancing immune function, health food for enhancing immune function, and lowering immune function. It is useful to use as a therapeutic agent for diseases caused by.
이하 본 발명을 설명한다.Hereinafter, the present invention will be described.
본 발명은 물로 추출된 닥나무 추출물을 유효성분으로 함유하는 면역기능 강화용 조성물을 제공한다.The present invention provides a composition for enhancing immune function, which contains the extract of the mulberry extract as water as an active ingredient.
또한, 본 발명은 상기 면역기능 강화용 조성물을 유효성분으로 함유하는 면역기능 강화용 건강식품을 제공한다.In addition, the present invention provides a health food for enhancing immune function containing the composition for enhancing immune function as an active ingredient.
또한, 본 발명은 상기 면역기능 강화용 조성물을 유효성분으로 함유하는 면역기능 저하로 기인하는 질환용 치료제를 제공한다.In addition, the present invention provides a therapeutic agent for diseases caused by a decrease in immune function containing the composition for enhancing immune function as an active ingredient.
아울러, 본 발명은 면역기능 저하로 인한 질환의 치료 방법을 제공한다.In addition, the present invention provides a method for the treatment of diseases caused by impaired immune function.
이하 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명은 물로 추출된 닥나무 추출물을 유효성분으로 함유하는 면역기능 강화용 조성물을 제공한다.The present invention provides a composition for enhancing immune function, which contains the extract of the mulberry extract as water as an active ingredient.
상기 닥나무 줄기를 수득하여 시료 중량의 약 1/5 내지 1 배, 바람직하게는 약 1/3배의 물을 추출용매로 이용하는 것이 바람직하다. 또한 실온에서 약 1 내지 24시간, 바람직하게는 4 내지 15시간 동안, 가장 바람직하게는 2 ~ 3시간 동안 추출하는 것이다. 추출 방법으로는 열수 추출, 냉침 추출, 환류 냉각 추출, 초음파 추출 및 증기 추출 등이 바람직하며, 더욱 바람직하게는 증기 추출 후 동결건조를 수행하므로써 본 발명의 닥나무 물 추출물을 수득할 수 있다. It is preferable to obtain the above-mentioned stems and use about 1/5 to 1 times, preferably about 1/3 times, water as the extraction solvent. The extraction is also performed at room temperature for about 1 to 24 hours, preferably 4 to 15 hours, most preferably 2 to 3 hours. The extraction method is preferably hot water extraction, cold extraction, reflux cooling extraction, ultrasonic extraction and steam extraction, more preferably by performing the lyophilization after steam extraction can be obtained the water extract of the mulberry tree of the present invention.
본 발명자들은 상기와 같이 추출된 닥나무 물 추출물이 생쥐의 비장 세포, 대식 세포의 생장에 미치는 영향을 조사하였다. 그 결과, 비장세포의 증식을 유발하며(도 1 및 표 1 참조), 대식 세포에서도 탁월한 증식 효과를 보이며, 양성 대조군에 비해서도 우월하게 효율적임을 확인하였다(도 2 및 표 2 참조). The present inventors investigated the effect of the water extract of the mulberry extract as described above on the growth of spleen cells, macrophages of mice. As a result, it induces the proliferation of splenocytes (see Fig. 1 and Table 1), showed an excellent proliferation effect also in macrophages, it was confirmed to be superior to the positive control (see Fig. 2 and Table 2).
이후 본 발명자들은 닥나무 물 추출물이 NO 생성에 미치는 영향을 조사하였다. 그 결과, NO 생성 또한 효과적으로 유발하여 면역 증강에 효과적임을 확인하였다(도 3 및 표 3 참조).The inventors then investigated the effect of the water extract of the mulberry on NO production. As a result, it was confirmed that the production of NO also effectively effective in boosting immunity (see FIG. 3 and Table 3).
그러므로 본 발명의 닥나무 물 추출물은 면역기능 강화용 조성물에 효율적으로 이용될 수 있다. Therefore, the water extract of the mulberry of the present invention can be efficiently used in the composition for enhancing immune function.
본 발명의 면역기능 강화용 조성물은 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. 목초액을 함유하는 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다.The composition for enhancing immune function of the present invention may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, oral formulations, external preparations, suppositories, and sterile injectable solutions. Carriers, excipients, and diluents that may be included in compositions containing wood vinegar include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 생약 추출액에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations may include at least one excipient such as starch, calcium carbonate, sucrose ( It is prepared by mixing sucrose or lactose and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
비경구 투여를 위한 제제에는 멸균된 수용액, 액제, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제, 주사제제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterile aqueous solutions, solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, suppositories, injections. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
또한, 본 발명은 상기 면역기능 강화용 조성물을 유효성분으로 함유하는 면역기능 강화용 건강식품을 제공한다.In addition, the present invention provides a health food for enhancing immune function containing the composition for enhancing immune function as an active ingredient.
닥나무 물 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 유제품, 음료, 껌, 차, 비타민 단일제, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.Examples of foods to which the water extract may be added include, for example, various foods, dairy products, beverages, gums, teas, vitamin monosaccharides, dietary supplements, etc. Can be.
또한, 면역기능 강화를 목적으로 식품 또는 음료에 첨가될 수 있다. 이 때, 식품 또는 음료 중의 상기 추출물의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 5 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다. It may also be added to foods or beverages for the purpose of enhancing immune function. At this time, the amount of the extract in the food or beverage can be added in 0.01 to 15% by weight of the total food weight, the health beverage composition is added in a ratio of 0.02 to 5 g, preferably 0.3 to 1 g based on 100 ml Can be.
본 발명의 건강 기능성 음료 조성물은 지시된 비율로 필수 성분으로서 상기 닥나무 물 추출물을 함유하는 외에는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 수크로오스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어 레바우디오시드 A, 글리시르히진등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.The health functional beverage composition of the present invention is not particularly limited to other ingredients except for containing the above-mentioned mulberry water extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. have. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 닥나무 물 추출물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜 릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 닥나무 물 추출물은 천연 과일 주스 및 과일 주스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 닥나무 100 중량부 당 0.1 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the mulberry water extract of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, such as flavoring agents, coloring and neutralizing agents (cheese, chocolate, etc.), pectic acid and salts thereof, Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, the mulberry water extract of the present invention may contain a flesh for preparing natural fruit juice and fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight of the mulberry of the present invention.
또한, 본 발명은 상기 면역기능 강화용 조성물을 유효성분으로 함유하는 면역기능 저하로 인한 질환용 치료제를 제공한다.In addition, the present invention provides a therapeutic agent for diseases caused by a decrease in immune function containing the composition for enhancing immune function as an active ingredient.
상기 면역기능 저하로 기인되는 질환으로는 감기 등의 감염성 질환 및 염증성 질환, 아토피 등의 알러지 질환, 만성피로, 암 등으로 이루어진 군으로부터 선택되는 어느 하나인 것이 바람직하나 이에 한정되는 것은 아니며, 당업자에 알려진 면역기능 저하로 기인되는 질환은 모두 본 발명에 포함된다. 본 발명의 닥나무 물 추출물의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 닥나무 물 추출물은 1일 0.0001 내지 500 ㎎/㎏으로, 바람직하게는 0.001 내지 500 ㎎/㎏으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The disease caused by the reduced immune function is preferably any one selected from the group consisting of infectious diseases such as cold and inflammatory diseases, allergic diseases such as atopic dermatitis, chronic fatigue, cancer and the like, but is not limited thereto. All diseases resulting from a known decrease in immune function are included in the present invention. Preferred dosages of the water extract of Methanol of the present invention vary depending on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration, and may be appropriately selected by those skilled in the art. However, for the desired effect, the water extract of the mulberry of the present invention is preferably administered at 0.0001 to 500 mg / kg, preferably at 0.001 to 500 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
아울러, 본 발명은 면역기능 저하로 인한 질환의 치료 방법을 제공한다.In addition, the present invention provides a method for the treatment of diseases caused by impaired immune function.
상기 치료 방법은 하기의 단계를 포함한다: 대상에 본 발명의 닥나무 물 추출물을 유효성분으로 투여하는 단계.The method of treatment comprises the following steps: administering the water extract of the mulberry of the present invention to the subject as an active ingredient.
상기 방법에 있어서, 본 발명의 닥나무 물 추출물은 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내(intracerebroventricular) 주사에 의해 투여될 수 있다. In the above method, the mulberry water extract of the present invention may be administered by various routes. All modes of administration may be expected, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine or intracerebroventricular injections.
이하, 본 발명을 실시예, 실험예 및 제제예에 의하여 상세히 설명한다.Hereinafter, the present invention will be described in detail by Examples, Experimental Examples and Formulation Examples.
단, 하기 실시예, 실험예 및 제제예는 본 발명을 구체적으로 예시하는 것이며, 본 발명의 내용이 실시예, 실험예 및 제제예에 의해 한정되는 것은 아니다.However, the following Examples, Experimental Examples, and Formulation Examples specifically illustrate the present invention, and the content of the present invention is not limited to Examples, Experimental Examples, and Formulation Examples.
<실시예 1> 닥나무(Example 1 Broussonetia kazinokiBroussonetia kazinoki Sieb.) 물 추출물 제조 Sieb.) Water Extract Manufacturer
닥나무 증기 추출액은 (주)천양제지에서 한지 제조 공정 중 생산되는 것을 수집하여 전주생물소재연구소에서 동결건조한 것을 사용하였다. 베어낸 닥나무 줄기를 1 - 1.5 m 길이를 잘라서 가지런히 한 다음 약 15 - 20 ㎏ 정도의 작은 단으로 묶어 직경 2 m, 깊이 1 m 정도의 철제 원통에 물을 1/3 정도 채운 후 닥나무를 세로로 세워 약 450-600 ㎏ 넣고 둘레를 움직이지 않게 단단히 고정시켰다. 외부를 비닐 씌워 증기가 빠져나가지 않도록 하고 증기의 공급으로 2-3시간 가열하였다. 충분히 쪄진 닥나무를 제거하고 원통 아래의 닥나무 추출액을 회수하여 감압농축시킨 후 동결건조하여 실험에 사용하였다. 건조된 닥나무 물 추출물의 수율은 1.3% 였다. The mulberry steam extract was collected from Cheonyang Paper Co., Ltd. during the manufacturing process of Hanji and used by lyophilization at Jeonju Biomaterials Research Institute.
<실험예 1> 생쥐 비장 세포의 세포증식 효과 조사Experimental Example 1 Investigation of Cell Proliferation Effect of Mouse Spleen Cells
7주령의 수컷 C57BL/6 마우스(대한바이오링크, 충북 음성)를 경추탈골 후 비장을 적출하였다. 적출한 비장을 HBSS(Hank's Balanced Salts Modified. Gbico BRL.)로 세척하고 세포 분리 후 원심분리하여 RBC 세포용해 버퍼(lysing buffer, Sigma)로 적혈구를 제거한 후 10% FBS(fetal bovine serum, Gibco BRL.)와 페니실린(penicillin, Gibco BRL.) 및 스트렙토마이신(streptomycin, Gibco BRL.)을 함유하는 RPMI 1640(Hyclone) 배지에 부유시켜 5% CO2, 37℃에서 배양하였다. 상기 실시예 1에서 제조된 닥나무 물 추출물이 비장 세포 증식에 미치는 효과를 검색하기 위하여 96-웰 플레이트(well plate)에 분리 배양한 비장 세포를 5×105 cells/well로 분주하고 닥나무 물 추출물을 1~100 μg/ml 농도로 PBS에 용해하여 첨가하였다. 세포증식 효과에 대한 비교물질로 ConA(Concanavalin A, Sigma Co., U.S.A)와 LPS(lipopolysaccharide, Sigma Co., U.S.A) 2 μg/ml로 각각 사용하였다. 48시간 배양 후 테트라졸리움 염인 CCK-8 kit(Cell Counting Kit-8, Dojindo Laboratories, Tokyo, Japan) 용액을 첨가하여 4시간 더 배양한 다음 ELISA 리더 기(Ceres UV 900C, Bio-tech instrument, U.S.A.)를 이용하여 450 nm에서 흡광도를 측정하였다. 대조군 웰(Control well)의 흡광도에 대한 약물첨가 well의 흡광도의 비를 %로 계산하였고, 여러 웰(well)의 평균값을 사용하였다. 계산식은 다음과 같다.Seven-week-old male C57BL / 6 mice (Korean Biolink, Chungbuk Negative) were extracted after the cervical spine bone. The extracted spleens were washed with HBSS (Hank's Balanced Salts Modified.Gbico BRL.), Centrifuged and separated to remove red blood cells with RBC lysing buffer (Sigma), followed by 10% FBS (fetal bovine serum, Gibco BRL. ) And penicillin (penicillin, Gibco BRL.) And streptomycin (streptomycin, Gibco BRL.) And suspended in RPMI 1640 (Hyclone) medium containing and cultured at 5% CO 2 , 37 ℃. In order to detect the effect of the water extract of the mulberry prepared in Example 1 on the spleen cell proliferation, the splenocytes separated and cultured in a 96-well plate were divided into 5 × 10 5 cells / well and the mulberry water extract was It was added by dissolving in PBS at a concentration of 1-100 μg / ml. As a comparison material for the cell proliferation effect, ConA (Concanavalin A, Sigma Co., USA) and LPS (lipopolysaccharide, Sigma Co., USA) were used as 2 μg / ml, respectively. After 48 hours of incubation, the solution was added with a solution of tetrazolium salt CCK-8 kit (Cell Counting Kit-8, Dojindo Laboratories, Tokyo, Japan) for 4 hours, followed by ELISA reader (Ceres UV 900C, Bio-tech instrument, USA). Absorbance was measured at 450 nm using. The ratio of the absorbance of drug addition wells to the absorbance of control wells was calculated in% and the average value of several wells was used. The calculation is as follows.
그 결과, 닥나무 물 추출물을 쥐에서 분리한 비장세포에 1~100 μg/ml로 처리하였을 때 비장세포의 증식효과가 농도의존적으로 증가되었다(도 1). 이는 양성대조군으로 사용한 LPS와 ConA를 2 μg/ml 처리한 경우 대조군의 203.4 ± 5.1, 224.9 ± 17.7%로 증가한 것으로 나타났으므로 닥나무 물 추출물은 비장세포의 증식을 유발하여 면역 증강에 효과적임을 확인하였다. As a result, the proliferation effect of the splenocytes was increased concentration-dependently when treated with 1 ~ 100 μg / ml to the spleen cells isolated from the rat water extract (March) (Fig. 1). This resulted in an increase of 203.4 ± 5.1 and 224.9 ± 17.7% of the control group when 2 μg / ml of LPS and ConA were used as the positive control group. .
<< 실험예Experimental Example 2> 생쥐 대식 세포주의 세포 증식 및 2> cell proliferation of mouse macrophage lines and NONO (( nitricnitric oxideoxide ) 생성 효과 조사Investigate the creation effect
<2-1> 생쥐 대식 세포주의 세포 증식 효과 조사<2-1> Investigation of Cell Proliferation in Mouse Macrophage Cell Line
쥐 대식 세포주(Murin macrophage cell line)인 Raw 264.7 세포주를 96-웰 플레이트에 5 × 103 cells/well로 분주하고 물 추출물을 1~100 μg/ml 농도로 처리하였다. 비교물질로는 ConA(Sigma Co., U.S.A)와 LPS(Sigma Co., U.S.A) 2 μg/ml로 각각 사용하였다. 48시간 배양 후 테트라졸리움 염인 CCK-8 kit(Cell Counting Kit-8, Dojindo Laboratories, Tokyo, Japan) 용액을 첨가하여 4시간 더 배양한 다음 ELISA 리더기(Ceres UV 900C, Bio-tech instrument, U.S.A.)를 이용하여 450 nm에서 흡광도를 측정하였다. 대조군 웰(Control well)의 흡광도에 대한 약물첨가 well의 흡광도의 비를 %로 계산하였고, 여러 웰(well)의 평균값을 사용하였다. 계산식은 다음과 같다.Raw 264.7 cell line, a Murin macrophage cell line, was dispensed in 96-well plates at 5 × 10 3 cells / well and treated with water extract at a concentration of 1-100 μg / ml. As a comparison material, ConA (Sigma Co., USA) and LPS (Sigma Co., USA) were used at 2 μg / ml, respectively. After 48 hours of incubation, add tetrazolium salt CCK-8 kit (Cell Counting Kit-8, Dojindo Laboratories, Tokyo, Japan) solution and incubate for 4 hours more, then use ELISA reader (Ceres UV 900C, Bio-tech instrument, USA). Absorbance at 450 nm was measured. The ratio of the absorbance of drug addition wells to the absorbance of control wells was calculated in% and the average value of several wells was used. The calculation is as follows.
그 결과, 닥나무 물 추출물을 생쥐 대식세포주인 RAW 264.7 세포주에 1~100 μg/ml로 처리하였을 때 세포증식효과가 양성대조군으로 사용한 LPS보다 높게 나타났으므로 닥나무 물 추출물은 대식세포의 증식을 유발하여 면역 증강에 효과적임을 확인하였다(도 2).As a result, when the mulberry water extract was treated with 1 ~ 100 μg / ml in the RAW 264.7 cell line, which is a mouse macrophage, the cell proliferation effect was higher than that of the LPS used as the positive control group. It was confirmed that it is effective for boosting immunity (FIG. 2).
<2-2> 생쥐 대식 세포주의 NO 생성 효과 조사<2-2> NO Production Effect of Mouse Macrophage Cell Line
Raw 264.7 세포를 2.5×105 cells/well로 48-웰 플레이트에 분주하여 CO2 배양기 내에서 24시간 배양한 후 양성 대조군으로 LPS를 농도별로 처리하였다. 약물 처리군에는 물 추출물을 1~100 μg/ml 로 처리하고 18시간 배양 후 상층액을 분리하고 NO 생성량을 측정하였다. NO 생성량은 Griess reagent(Promega, U.S.A)를 이용하여 반응시켰으며 535 nm에서 흡광도를 측정하였다.Raw 264.7 cells were aliquoted into 2.5 × 10 5 cells / well in 48-well plates, incubated in CO 2 incubator for 24 hours, and treated with LPS by concentration as a positive control. In the drug treatment group, water extract was treated with 1-100 μg / ml, the supernatant was separated after 18 hours of incubation, and NO production was measured. NO production was reacted using Griess reagent (Promega, USA) and the absorbance was measured at 535 nm.
그 결과, 닥나무 물 추출물을 생쥐 대식세포주인 RAW 264.7 세포주에 1~100 μg/ml로 처리하였을 때 NO 생성 촉진효과가 우수한 것으로 나타났다. 닥나무 물 추출물은 대식세포의 증식을 유발할 뿐만 아니라 대식세포에서 NO의 생성도 촉진하여 면역 증강에 효과적임을 확인하였다(도 3).As a result, when the water extract of the mulberry tree was treated with 1 ~ 100 μg / ml in the RAW 264.7 cell line, which is a mouse macrophage, the NO production promoting effect was excellent. It was confirmed that the water extract of mulberry not only induces the proliferation of macrophages but also promotes the production of NO in the macrophages and is effective in enhancing immunity (FIG. 3).
상기 결과를 통해 본 발명의 닥나무 물 추출물이 생쥐 비장세포의 세포증식, 대식세포의 증식, 대식세포의 NO 생성 촉진에 대해 우수한 효과를 나타냈으므로 본 발명의 닥나무 물 추출물은 면역 활성화 및 면역 기능 강화에 사용될 수 있음을 제시한다. According to the above results, the water extract of the present invention showed the excellent effect on the cell proliferation of the mouse splenocytes, the proliferation of macrophages, the promotion of NO production of macrophages, the water extract of the present invention is the immune activation and immune function enhancement It can be used for.
하기에 본 발명의 조성물을 위한 제제예를 예시한다.Examples of formulations for the composition of the present invention are illustrated below.
<제제예 1> 약학적 제제의 제조Preparation Example 1 Preparation of Pharmaceutical Formulation
<1-1> 산제의 제조 <1-1> Preparation of powders
본 발명의 닥나무 물 추출물 2 g2 g of young water extract of the present invention
유당 1 g1 g lactose
상기의 성분을 혼합한 후, 기밀포에 충진하여 산제를 제조하였다.After mixing the above components, the airtight cloth was filled to prepare a powder.
<1-2> 정제의 제조 <1-2> Preparation of Tablet
본 발명에 따른 닥나무 물 추출물 100 ㎎100 mg of water extract according to the present invention
옥수수전분 100 ㎎
유 당 100 ㎎
스테아린산 마그네슘 2 ㎎2 mg magnesium stearate
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
<1-3> 캡슐제의 제조 <1-3> Preparation of Capsule
본 발명의 닥나무 물 추출물 100 ㎎100mg of Methanol Water Extract of the Invention
옥수수전분 100 ㎎
유 당 100 ㎎
스테아린산 마그네슘 2 ㎎2 mg magnesium stearate
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
<1-4> 주사액제의 제조 <1-4> Preparation of Injection Solution
본 발명에 따른 닥나무 물 추출물 10 ㎍/㎖10 ㎍ / ml of the water extract of the mulberry according to the present invention
묽은 염산 BP pH 3.5로 될 때까지Dilute hydrochloric acid BP until pH 3.5
주사용 염화나트륨 BP 최대 1 ㎖Injectable sodium chloride BP up to 1 ml
적당한 용적의 주사용 염화나트륨 BP 중에 본 발명에 따른 목이버섯 균사체 분말을 용해시키고, 생성된 용액의 pH를 묽은 염산 BP를 사용하여 pH 3.5로 조절하고, 주사용 염화나트륨 BP를 사용하여 용적을 조절하고 충분히 혼합하였다. 용액을 투명 유리로 된 5 ㎖ 타입 I 앰플 중에 충전시키고, 유리를 용해시킴으로써 공기의 상부 격자하에 봉입시키고, 120 ℃에서 15 분 이상 오토클래이브시켜 살균하여 주사액제를 제조하였다.Dissolve the wood mushroom mycelium powder according to the present invention in an appropriate volume of sodium chloride BP for injection, adjust the pH of the resulting solution to pH 3.5 with dilute hydrochloric acid BP, and adjust the volume with sodium chloride BP for injection and sufficiently Mixed. The solution was filled into a 5 ml Type I ampoule made of clear glass, encapsulated under an upper grid of air by dissolving the glass, and sterilized by autoclaving at 120 ° C. for at least 15 minutes to prepare an injection solution.
<< 제제예Formulation example 2> 식품의 제조 2> Manufacture of food
본 발명에 따른 본 발명의 닥나무 물 추출물을 포함하는 식품들을 다음과 같이 제조하였다.Foods comprising the water extract of the mulberry of the present invention according to the present invention were prepared as follows.
<2-1> 밀가루 식품의 제조 <2-1> Preparation of Flour Food
본 발명의 닥나무 물 추출물 0.1 ~ 10.0 중량부를 밀가루에 첨가하고, 이 혼합물을 이용하여 통상의 방법으로 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.0.1 ~ 10.0 parts by weight of the water extract of the mulberry of the present invention was added to the flour, and using the mixture, bread, cake, cookies, crackers and noodles were prepared in a conventional manner to prepare foods for health promotion.
<2-2> 스프 및 육즙(gravies)의 제조 <2-2> Preparation of Soups and Gravys
본 발명의 닥나무 물 추출물 0.1 ~ 1.0 중량부를 스프 및 육즙에 첨가하여 통상의 방법으로 건강 증진용 육가공 제품, 면류의 수프 및 육즙을 제조하였다.0.1-1.0 parts by weight of the water extract of Methanol of the present invention was added to soups and gravy to prepare meat products for health promotion, soup of noodles and gravy in a conventional manner.
<2-3> 그라운드 비프(ground beef)의 제조 <2-3> Preparation of Ground Beef
본 발명의 닥나무 물 추출물 10 중량부를 그라운드 비프에 첨가하여 통상의 방법으로 건강 증진용 그라운드 비프를 제조하였다.10 parts by weight of the water extract of the mulberry of the present invention was added to the ground beef to prepare a ground beef for health promotion in a conventional manner.
<2-4> 유제품( dairy products )의 제조 <2-4> dairy products (dairy products )
본 발명의 닥나무 물 추출물 0.1 ~ 1.0 중량부를 우유에 첨가하고, 상기 우유를 이용하여 통상의 방법으로 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.0.1-1.0 parts by weight of the water extract of Methanol of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared in a conventional manner using the milk.
<2-5> 선식의 제조 <2-5> Preparation of Wire
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.
검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.
본 발명의 닥나무 물 추출물을 진공 농축기에서 감압, 농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.The water extract of the present invention was concentrated under reduced pressure and concentrated in a vacuum concentrator, and dried by spraying and drying with a hot air dryer to grind the dried product to a particle size of 60 mesh using a grinder to obtain a dry powder.
상기에서 제조한 곡물류, 종실류 및 본 발명에 따른 목이버섯 균사체 분말을 다음의 비율로 배합하여 통상의 방법으로 제조하였다.The grains, seeds and the mycelium mycelium mycelium powder according to the present invention were prepared in the following ratio to prepare a conventional method.
곡물류(현미 30 중량부, 율무 15 중량부, 보리 20 중량부),Cereals (30 parts by weight brown rice, 15 parts by weight brittle, 20 parts by weight of barley),
종실류(들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)
본 발명의 닥나무 물 추출물(1 중량부),Methanol water extract of the present invention (1 part by weight),
영지(0.5 중량부),(0.5 part by weight),
지황(0.5 중량부)Foxglove (0.5 part by weight)
<< 제제예Formulation example 3> 음료의 제조 3> Manufacturing of beverage
본 발명의 닥나무 물 추출물을 포함하는 음료를 다음과 같이 제조하였다.Drinks containing the water extract of the mulberry of the present invention was prepared as follows.
<3-1> 건강음료의 제조 <3-1> Preparation of Health Beverage
액상과당(0.5%), 올리고당(2%), 설탕(2%), 식염(0.5%), 물(75%)과 같은 부재료와 본 발명에 따른 닥나무 물 추출물을 균질하게 배합하여 순간 살균을 한 후, 이를 유리병, 패트병 등 소포장 용기에 포장하여 건강음료를 제조하였다.Instant sterilization was carried out by homogeneously mixing the ingredients such as liquid fructose (0.5%), oligosaccharides (2%), sugar (2%), salt (0.5%), water (75%) and the water extract of the mulberry according to the present invention. Then, it was packaged in a small packaging container such as glass bottles, plastic bottles to prepare a healthy beverage.
<3-2> 야채쥬스의 제조 <3-2> Preparation of Vegetable Juice
본 발명의 닥나무 물 추출물 0.5 g을 토마토 또는 당근 등의 야채의 쥬스 1,000 ㎖에 가하여 통상의 방법으로 건강 증진용 야채쥬스를 제조하였다.0.5 g of the water extract of the present invention was added to 1,000 ml of vegetable juices such as tomatoes or carrots to prepare vegetable juice for health promotion in a conventional manner.
<3-3> 과일쥬스의 제조 <3-3> Preparation of Fruit Juice
본 발명의 닥나무 물 추출물 0.1 g을 사과 또는 포도 등의 과일의 쥬스 1,000 ㎖에 가하여 통상의 방법으로 건강 증진용 과일쥬스를 제조하였다.0.1 g of the water extract of the mulberry of the present invention was added to 1,000 ml of fruit juices such as apples or grapes to prepare fruit juice for health promotion in a conventional manner.
도 1은 생쥐 비장세포에서 본 발명의 닥나무 물 추출물 처리에 따른 비장세포의 증식 효과를 나타내는 그래프이다.1 is a graph showing the proliferative effect of splenocytes according to the treatment of the water extract of the present invention in the mouse splenocytes.
도 2는 생쥐 대식세포주에서 본 발명의 닥나무 물 추출물 처리에 따른 대식세포주의 증식 효과를 나타내는 그래프이다.Figure 2 is a graph showing the proliferation effect of the macrophage cell line according to the treatment of the water extract of the present invention in the mouse macrophage line.
도 3은 생쥐 대식세포주에서 본 발명의 닥나무 물 추출물 처리에 따른 NO 생성 유발 효과를 나타내는 그래프이다. Figure 3 is a graph showing the NO production inducing effect according to the treatment of the water extract of the present invention in the mouse macrophage line.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080088388A KR101039110B1 (en) | 2008-09-08 | 2008-09-08 | A water composition comprising Broussonetia kazinoki Sieb. for immunopotentiating |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020080088388A KR101039110B1 (en) | 2008-09-08 | 2008-09-08 | A water composition comprising Broussonetia kazinoki Sieb. for immunopotentiating |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100029559A KR20100029559A (en) | 2010-03-17 |
KR101039110B1 true KR101039110B1 (en) | 2011-06-15 |
Family
ID=42179765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080088388A KR101039110B1 (en) | 2008-09-08 | 2008-09-08 | A water composition comprising Broussonetia kazinoki Sieb. for immunopotentiating |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101039110B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220029828A (en) | 2020-08-28 | 2022-03-10 | 엠테라파마 주식회사 | A composition for improving insulin sensitivity comprising extract of broussonetia kazinoki |
KR20220064448A (en) | 2020-11-11 | 2022-05-19 | 엠테라파마 주식회사 | A composition for improving insulin sensitivity comprising mixture of herbal extracts of broussonetia kazinoki and juglans mandshurica |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101692889B1 (en) * | 2014-01-09 | 2017-01-04 | 한국생명공학연구원 | Composition comprising an extract or a fraction of Daphne kamtschatica for preventing or treating inflammatory diseases |
KR101649047B1 (en) | 2014-12-08 | 2016-08-17 | 숙명여자대학교산학협력단 | Use of Kazinol C for treating or preventing cancer |
KR102252129B1 (en) * | 2020-11-10 | 2021-05-14 | 엠테라파마 주식회사 | Composition for preventing or treating inflammatory bowel disease comprising herbal extract of broussonetia kazinoki |
-
2008
- 2008-09-08 KR KR1020080088388A patent/KR101039110B1/en active IP Right Grant
Non-Patent Citations (1)
Title |
---|
Korean J. Soc. Food Sci. 15(3), 231~237 (1999.08.)* |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220029828A (en) | 2020-08-28 | 2022-03-10 | 엠테라파마 주식회사 | A composition for improving insulin sensitivity comprising extract of broussonetia kazinoki |
KR20220064448A (en) | 2020-11-11 | 2022-05-19 | 엠테라파마 주식회사 | A composition for improving insulin sensitivity comprising mixture of herbal extracts of broussonetia kazinoki and juglans mandshurica |
Also Published As
Publication number | Publication date |
---|---|
KR20100029559A (en) | 2010-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101160943B1 (en) | Health functional foods compositions for the prevention and amelioration of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient | |
KR101613693B1 (en) | Composition for Prevention or Treatment of Skin Disease Comprising an Extract of Sargassum Horneri and Method of Preparing The Same | |
KR20120007275A (en) | Composition comprising plants extract mixture for immune enhancement | |
KR102366919B1 (en) | Functional health food composition for inhibiting muscle reduction comprising a mixed extract of mulberry twig, Eucommia bark, Acanthopanax, and black bean | |
KR101184666B1 (en) | Composition for improving physiological activity of positive constitution | |
KR20180108331A (en) | Method for improving periodontitis and alveolar bone loss of complex extracts of Moringa leaf and Eucommia Bark by anti-bacterial, antioxidant, anti-inflammatory, antioxidant effects and inhibition of alveolar bone loss | |
KR101045031B1 (en) | A composition comprising fruits of Cudrania tricuspidata for immunopotentiating | |
KR101484021B1 (en) | A Composition Comprising the extract of combined herbs including Curcuma Longa L. for immuno-stimulating activity | |
KR101039110B1 (en) | A water composition comprising Broussonetia kazinoki Sieb. for immunopotentiating | |
KR20110127443A (en) | Composition for anti-obesity and antioxidant comprising camellia japonica flower extract as active ingredient | |
JP5409439B2 (en) | Composition for enhancing immune function, comprising Kouzo extract | |
KR20140017932A (en) | Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange | |
KR101018403B1 (en) | composition comprising the extract of soybean leaves for the prevention?delay or treatment of gout | |
KR100542876B1 (en) | Composition comprising Schizandrae Fructus extract as an effective component for preventing and treating arthritis | |
KR101525877B1 (en) | A composition for preventing wrinkle of skin and anti aging of skin | |
KR101207239B1 (en) | A composition for the prevention and treatment of inflammatory disease comprising the fractions of Asparagus cochinchinensis as an active ingredient | |
KR100555904B1 (en) | A herbal mixture extract of Pleurotus eryngii and Acanthopanacis Cortex and composition comprising the same for prevention and treatment of osteoporosis | |
KR101033003B1 (en) | A composition comprising Broussonetiae Fructus for immunopotentiating | |
KR101456127B1 (en) | A composition for increasing bone growth | |
KR101044717B1 (en) | Composition containing extract of soybean leaves for prevention, delay or treatment of diabetes | |
KR101257909B1 (en) | Pharmaceurtical compositions for the prevention or treatment of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient | |
KR101712889B1 (en) | Pharmaceutical composition comprising Zingiber mioga extracts or its fractions for prevention and treatment of neurodegenerative disorders as an active ingredient | |
KR100533283B1 (en) | Composition comprising extract of herbal mixture for prevention or treatment of osteoporosis | |
CN102188489A (en) | Composition containing fructus broussonetiae extract for strengthening immune function | |
KR102185006B1 (en) | A composition for improving, preventing and treating of asthma and vascular disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140316 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160405 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20180530 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190325 Year of fee payment: 9 |